<DOC>
	<DOC>NCT00666718</DOC>
	<brief_summary>This study is designed to look at if a basal bolus regimen of insulin lispro protamine suspension (ILPS) provides the same glycemic control as a basal bolus regimen of insulin glargine (when one basal bolus regimen is injected once daily together with insulin lispro injected 2-3 times daily).</brief_summary>
	<brief_title>A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>Diabetes Mellitus, Type 2 Have been receiving metformin and at least one other oral antihyperglycemic medication (sulfonylurea or thiazolidinedione) with insulin for at least 3 months prior to Visit 1 (Screening) Hemoglobin A1C (HbA1c) greater than or equal to 7.5% and less than or equal to 11.0% Body Mass Index (BMI) greater than or equal to 25 and less than or equal to 45 kg/m^2 Capable and willing to follow the protocol Give written consent Are taking any glucoselowering agents (other than those listed in the inclusion criteria above) Have a history of severe hypoglycemia in the past 6 months Are pregnant or may become pregnant Women who are breastfeeding Have significant cardiac disease Have significant renal or liver disease Undergoing therapy for a malignancy Contraindications to the study medications Have an irregular sleep/wake cycle Have a serious disease or any condition considered by the investigator to be exclusionary</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>